Chinese diagnostics manufacturer expands global footprint across Southeast Asia, Middle East, Africa, and Latin America
BANGKOK, Thailand – July 16, 2026 – Hangzhou Testsea Biotechnology Co., Ltd. (Testsea), a leading Chinese IVD manufacturer, successfully participated in the WHX World Health Expo Bangkok 2026, held July 8‑10 at the Queen Sirikit National Convention Center. The event is one of Southeast Asia’s most influential healthcare exhibitions, attracting global players in medical devices, diagnostics, and digital health. Testsea leveraged this platform to present its full range of rapid test solutions, covering infectious diseases, women’s health, fertility, chronic disease management, and gastrointestinal disorders. The company engaged with distributors and healthcare professionals from over 20 countries across Southeast Asia, the Middle East, Europe, Africa, and Latin America, generating strong interest and numerous follow‑up discussions.
Key Product Highlights
6‑in‑1 Respiratory Combo Test – TGA Approved
The most featured product was the 6‑in‑1 Respiratory Antigen Combo Test, which simultaneously detects Influenza A, Influenza B, COVID‑19, Human Metapneumovirus (HMPV), Respiratory Syncytial Virus (RSV), and Adenovirus from a single nasal swab. Results are available in approximately 10 minutes, making it ideal for point‑of‑care, pharmacy, and home use.
This test has received full registration from the Australian Therapeutic Goods Administration (TGA) – the first and only at‑home multiplex respiratory test authorised in Australia. This regulatory milestone not only validates its clinical performance but also positions the product for future registrations in other regulated markets such as the EU and the UK.
Infectious Disease Rapid Tests
Testsea also showcased its expanding infectious disease portfolio, including:
- HIV Urine Test – available in cassette and pen formats, this needle‑free, non‑invasive test ensures privacy and ease of use, suitable for home testing and community screening programs.
- Pre‑surgery 4‑in‑1 Panel – combining HIV, HBsAg, HCV, and Syphilis in a single test, it significantly improves pre‑operative screening efficiency.
- Dengue IgG/IgM + NS1 Combo – addressing the rising burden of dengue fever in tropical regions, this combo enables earlier and more accurate diagnosis.
Women’s Health Solutions
Recognising the growing femtech market, Testsea presented an integrated women’s health product line:
- HPV 16/18 + L1 Antigen Combo Test for cervical cancer risk assessment.
- Anti‑HPV Functional Protein Gel as a topical adjuvant post‑screening.
- Vaginitis Triple‑Combo Test for differential diagnosis of bacterial vaginosis, candidiasis, and trichomoniasis.
- Chlamydia/Gonorrhea Duo Test for STI screening.
This approach – from screening to intervention – offers a complete care pathway for women’s health.
Digital Fertility and Chronic Disease Management
The Digital HCG/LH Test Pen features an LCD display that eliminates subjective colour reading, making it user‑friendly for fertility tracking at home.
For chronic conditions, Testsea displayed a series of multi‑parameter monitors, including a glucose meter, a 4‑in‑1 device measuring glucose, uric acid, blood pressure, and heart rate, and a lipid panel covering glucose, uric acid, total cholesterol, and triglycerides. These devices are designed for home health management and primary care settings.
Gastrointestinal Combo Panels
Two combination panels were introduced for digestive health screening:
- H. pylori + Faecal Occult Blood + Transferrin
- Faecal Occult Blood + Transferrin + Calprotectin
Both panels are designed for easy stool sample processing and deliver results in just 5 minutes, enabling rapid clinical decision‑making.
OEM/ODM Capabilities
Beyond finished products, Testsea emphasised its comprehensive one‑stop OEM/ODM services, including custom product development, packaging design, private labelling, regulatory documentation support, and agile delivery. With a 10,000+ m² GMP‑compliant manufacturing facility in Hangzhou and an annual production capacity of over 50 million tests, the company is well‑equipped to support global partners with high‑quality, cost‑effective solutions.
Currently, Testsea exports to more than 100 countries and regions, serving ministries of health, NGOs, hospitals, and private laboratory chains across five continents.
Award
The Testsea booth received a bronze award at the expo in recognition of its exhibition design.
About Testsea
Founded in 2015, Hangzhou Testsea Biotechnology Co., Ltd. is a high‑tech enterprise specialising in the R&D, production, and global distribution of IVD rapid tests. Leveraging talent and technology from Zhejiang University and the Chinese Academy of Sciences, the company maintains strong collaborations with academic institutions and industry partners. With over 200 SKUs currently available, Testsea is committed to delivering reliable, affordable diagnostic solutions worldwide.
Post time: Jul-17-2026